Eurobench.com

[verwijderd] 27 april 2009 22:54

0

Alarmfase vier wegens varkensgriep
Uitgegeven: 27 april 2009 22:46
Laatst gewijzigd: 27 april 2009 22:46
www.nu.nl/algemeen/1955736/alarmfase-...
GENEVE - De Wereldgezondheidsorganisatie (WHO) heeft maandagavond tijdens spoedoverleg in Geneve het alarmniveau voor de dodelijke varkensgriep verhoogd van fase drie naar vier.

Oorspronkelijk zou de bijeenkomst dinsdag worden gehouden, maar de WHO besloot wegens de situatie in Mexico eerder bijeen te komen.

Volgens de VN-organisatie is het risico op een pandemie wezenlijk toegenomen. Hele gemeenschappen kunnen worden geraakt door besmetting van mens op mens.

Verspreiding

De WHO wil nu de nadruk leggen op het tegengaan van de verspreiding van het nieuwe virus. Landen wordt gevraagd reisadviezen en controles van reizigers te overwegen.

Getroffen landen zouden vaccinatiecampagnes moeten overwegen, evenals beperking van de bewegingsvrijheid van personen in besmet gebied.

[verwijderd] 28 april 2009 10:07

0

Volg de varkensgriep via Google earth.

www.telegraaf.nl/buitenland/3799430/_...,1

www.telegraaf.nl/jsp/foto_window.jsp?...

Dirk

flosz 28 april 2009 10:19

0

[modbreak Paul forum@iex.nl: Even de link in 2 stukjes gehakt om de pagina leesbaar te houden.]

Dank je wel, service hoor!
********************
@ dirk
Link van pag.8 werkt zonder Telegraaf-tussenkomst.
www.idemc.org/

flosz 28 april 2009 10:33

0

Sanofi ready, willing and able — but a vaccine will take time
By HOWARD FRANK
Pocono Record Writer
April 28, 2009
Swiftwater vaccine maker Sanofi Pasteur is ready to help health agencies develop a vaccine to neutralize the swine influenza reported here and in other parts of the world — as soon as they're given the go-ahead.
In a written statement, the company said: "In the event that WHO (the World Health Organization) and other health authorities identify the need for a specific swine influenza A/H1N1 vaccine, Sanofi Pasteur is ready to work with health and regulatory authorities to develop a vaccine candidate."
But it won't happen fast.
"What I can tell you is that under our anticipated manufacturing time cycle, the first doses of any influenza vaccine should become available a few months after delivery of the viral strain, provided that the manufacturers also have received the relevant reagents from a WHO reference center in due time. Of course, we would work closely with health authorities to make every effort to shorten the time for vaccine availability," Ellyn Schindler, a spokesperson for Sanofi Pasteur, said.
Until they begin working with the seed virus and are able to characterize its potential yield, it would be speculative to provide any reliable time frame, she added.
Sanofi hasn't been asked to work on a vaccine yet, but preparations are being made in case such a request is made.
"We have been and continue to be in active in discussions with (U.S.) public health officials on this topic, and the authorities are taking the necessary steps to be able to make such a request if it should prove necessary," Schindler said.
It's a rapidly evolving situation and Schindler said it's Sanofi's understanding that the U.S. Centers for Disease Control, the WHO and the European CDC are still working to isolate the genetic characteristics of all the virus strains identified so far. That has to happen before selecting and producing seed that could be used for vaccine production.
The ball is in the world health organizations' court.
"When they have the necessary information to determine if vaccine production would be beneficial, they know we are standing by and they will contact us. Until then, Sanofi Pasteur, as the world's leading producer of influenza vaccine, is coordinating closely with these agencies and maintaining its capabilities at a high state of readiness, should health authorities request support from influenza vaccine manufacturers," Schindler said.
www.poconorecord.com/apps/pbcs.dll/ar...

**************
Operationeel deeldraaiboek 2.
Incidentele introductie nieuw humaan influenzavirus in Nederland

www.rivm.nl/cib/binaries/DB%20Intr%20... class=

flosz 28 april 2009 13:18

1

Top Swine Flu Stocks

Swine Flu Stock #3: Crucell

Crucell (CRXL) is the 21st-century vaccine technology company, and its business model is to be the "Intel Inside" for many vaccine makers. Crucell owns a traditional vaccine business and is also developing new vaccines for many infectious diseases.
Its technology platform -- cell-line manufacturing -- is much more efficient than traditional egg-based vaccine production, and the company has partnered with many of the major players in the vaccine business.

www.optionszone.com/trading-ideas/200...

[verwijderd] 28 april 2009 13:20

0

Vical Updates Lead Vaccine Programs At NFID Vaccine Research Conference and Addresses Potential Response to H1N1 Swine Influenza Outbreak
On Tuesday April 28, 2009, 6:30 am EDT

BALTIMORE, April 28, 2009 (GLOBE NEWSWIRE) --

Vical Incorporated (NasdaqGM:VICL - News) today announced that the company's Vice President of Vaccine Research, Larry R. Smith, Ph.D., is presenting updates on the company's pandemic influenza and cytomegalovirus (CMV) vaccine programs at the 12th Annual Conference on Vaccine Research sponsored by the National Foundation for Infectious Diseases (Baltimore, April 27 - 29).

"Phase 1 Safety and Immunogenicity Results of Vaxfectin(r)-formulated Plasmid DNA Vaccines Encoding Influenza Virus H5 Hemaggluntinin,'' an oral presentation, summarizes results from the company's successful Phase 1 trial and future goals for its pandemic influenza DNA vaccine program. The double-blind, placebo-controlled, dose-escalation Phase 1 trial was conducted in approximately 100 healthy volunteers age 18 to 45 at three U.S. clinical sites. The trial was designed to assess safety and immunogenicity following vaccination, and to evaluate monovalent and trivalent Vaxfectin(r)-formulated H5N1 pandemic influenza DNA vaccines at various doses. The vaccines were safe and well tolerated in the trial, and induced antibody responses and T-cell responses against a matching strain of influenza virus, and cross-clade antibody responses against different strains.

The current public health emergency caused by outbreaks of H1N1 swine influenza highlights the need for a faster method to develop and produce vaccines. Vical's technology could produce a vaccine within six to nine weeks after the H1 hemagglutinin gene is sequenced. If the U.S. government or an international health agency issues a directive and provides the necessary resources, Vical is prepared to respond. In its broader pandemic influenza effort, Vical is currently exploring potential sources of funding for further development. The company's near-term goals are to confirm vaccine safety and immunogenicity in a larger number of subjects, optimize vaccine dose and adjuvant ratio, explore prime-boost regimens with different vaccines, and leverage the Phase 1 proof of concept for its DNA vaccine platform and Vaxfectin(r) adjuvant into additional indications.

En aanvullend moeten ze de boer op om dit te financieren.

Vical Exploring Funding For Pandemic Flu Effort >VICL

Last update: 4/28/2009 6:32:51 AM(MORE TO FOLLOW)

Dow Jones Newswires (201-938-5400)April 28, 2009 06:32 ET (10:32 GMT)Copyright © 2009 MarketWatch, Inc. All rights reserved. Please see our Terms of Use.

Dirk

flosz 28 april 2009 13:31

0

Wow, Trudy is boos….

Van nostra (www.ErikErik.com)
www.crazymonkeygames.com/jkf6Tr/pande...

B_B 28 april 2009 13:37

2

Flu Vaccine: Drugmakers Could Be Ready Soon
Fears over infectious outbreaks, from SARS to bird flu to the latest swine-borne virus, have boosted investment in vaccines and fostered fresh approaches
By John Carey

No one knows yet whether the flu outbreak in Mexico and in states like New York and California will turn into a major pandemic or a forgettable blip in the annals of infectious diseases. It's not even clear exactly what to call the virus, since it seems to have acquired genes from both pigs and birds on its evolutionary journey to making people sick. "As far as we know, this never happened before," says Laurie A. Garrett, senior fellow at the Council on Foreign Relations and author of The Coming Plague: Newly Emerging Diseases in a World Out of Balance. Maybe we should call it the swinebird flu.

The good news is that the world—especially the vaccine industry—is far better prepared to deal with a threat such as the new influenza virus than it was just a few years ago. Key decisions to rush through a vaccine have yet to be made. But governments around the world could move quickly to tap the industry's capability if the outbreak continues to worsen. One scenario floated by the Centers for Disease Control in Atlanta: The U.S. government could direct a drug company to drop some of its current development projects, create a swine flu vaccine, and start ramping up manufacturing.

An action like that would be costly and politically fraught. But the surprising thing is that such a step is even possible. That certainly was not the case during the flu season of 2004-2005. Back then, the pharmaceutical industry couldn't make enough vaccine for regular flu. There were only two companies in the business—Aventis Pasteur (now a unit of Sanofi-Aventis (SNY)) and Chiron (since acquired by Novartis (NVS)). One of Chiron's facilities had to be shut down during that outbreak because of safety concerns.

Egg-Cultivated Vaccines Take Time
What has occurred in the interim is a vaccine revival fueled by both improved profitability and an increase in government dollars. Three pharmaceutical giants now manufacture flu vaccine: Sanofi-Aventis, Novartis, and GlaxoSmithKline (GSK), along with small players such as MedImmune, a unit of AstraZeneca (AZN). These companies are already gearing up to make the vaccine for next winter's flu season. There's enough capacity among the players to ramp up production of swine flu vaccine—assuming funding is available—and still prepare for the regular flu season.

The bad news? The latest threat can't be squelched quickly or completely with a vaccine produced by traditional methods. The manufacturing process takes months because the virus first must be carefully grown in eggs, then harvested to be turned into a vaccine.

Yet there's possibly a way around this problem. Over the past few years, several companies have sprung up to develop methods for making vaccines more quickly, such as growing viruses in cells rather than eggs. These processes hold considerable promise, but none has been licensed yet by the Food & Drug Administration. One of the difficult decisions the Obama Administration will face if the epidemic threatens to spin out of control is whether to fast-track approval of one of these next-generation vaccines in order to make it available more quickly. "If this turns out to be a crisis, the government might go to one of the newer technologies that has quicker production," explains John Clerici, chair of the life sciences and public health practice at law firm McKenna Long & Aldridge. The bigger the crisis, the greater the tolerance for regulatory risks.

www.businessweek.com/technology/conte...

flosz 28 april 2009 13:42

0

PlanFirst Webcasts on Pandemic Influenza

The scheduled Webcast on State-based public health pandemic planning accomplishments and efforts has been postponed. There will be a Webcast on Wednesday, April 29th at 2 p.m. ET. on the current swine flu situation. Details about the Webcast will be provided as soon as they become available.
www.pandemicflu.gov/news/panflu_webin...
************************
These samples, which can then be distributed to companies, must be grown in specially produced chicken eggs in a cumbersome system that experts agree is outdated. New and more efficient technologies based on cell cultures are, however, still a few years away.
While the race is on to prepare a pandemic vaccine, health authorities and companies still have to make the tricky decision of when, or indeed whether, to switch capacity from producing seasonal vaccines to making the new shot.
"If you go to pandemic flu production, people won't get normal flu shots -- it is a huge consideration," said WHO spokesman Gregory Hartl.
At least 20 companies, in addition to Novartis, make flu vaccines, including Sanofi-Aventis, GlaxoSmithKline, Baxter International, Australia's CSL and nasal spray maker MedImmune, now part of AstraZeneca.
They are currently geared to producing season flu shots, which vaccine specialists say will not stop the new form of swine flu spreading around the world, although people who have been immunised may end up with milder symptoms.
So-called swine flu is a variant of the H1N1 form of the human influenza virus, but tests show the H1N1 component of the current seasonal flu vaccine does not protect against the new strain.
A big challenge facing manufacturers will be making sufficient quantities of vaccine from a limited supply of active ingredient, or antigen.
One option to extend supply is to use an additive, known as an adjuvant, to increase the body's immune response and reduce the amount of antigen needed in each shot.
Several companies are working on this approach. Glaxo, in particular, said it believed its novel adjuvant technology could make a significant contribution to antigen sparing.
The British company previously developed a vaccine against the H5N1 strain of bird flu -- originally thought to pose the biggest pandemic threat -- using a special adjuvant that allowed an extremely low dose of active ingredient to be used.
Credit Suisse analysts said companies with the know-how to make pandemic flu vaccines stood to benefit from additional sales, adding there could also be an increase in seasonal flu vaccine demand as disease awareness increases.
uk.reuters.com/article/swineFluH1N1/i...

ved 28 april 2009 14:01

2

As an influenza vaccine manufacturer Crucell is aware of the current situation in Mexico and other affected countries. Crucell is in active dialogue with the relevant governmental authorities and non governmental organizations (NGOs), while suitable actions to the situation are being decided. As an active member of the International Vaccine Supply Task Force and the International Federation of Pharmaceutical Manufacturers and Associations, Crucell will work with other industry members, health authorities and NGOs to respond as rapidly as possible and in accordance with key recommendations made by the World Health Organization (WHO). In response to a request from the Pan American Health Organization, Crucell is looking to mobilize remaining (limited) stocks of its 2008/2009 seasonal vaccine Inflexal® V for supply to Mexico. Although at this stage it is not clear if existing seasonal flu vaccines induce protective immunity to the currently circulating H1N1 swine flu virus strain. The situation appears to be evolving rapidly, therefore Crucell's response will be tailored to support the public health needs, once more information becomes available, and as directed by organizations such as the WHO.

Crucell has an active influenza R&D program to improve the prevention and treatment of seasonal and pandemic influenza:

Crucell is testing new adjuvants and new routes of administration in humans for virosome-based pandemic influenza vaccines in the EU (Panfluvac program).
Sanofi Pasteur is using Crucell's PER.C6® technology to produce the next generation influenza vaccines.
Crucell has discovered human monoclonal antibodies broadly protecting against H1 strains to which family the current swine flu virus belongs. The most potent and broadly reactive of these antibodies is currently being prepared for clinical testing.
www.crucell.com/feature_Swineflu_stat...

flosz 28 april 2009 14:03

0

quote:
ved schreef:
As an influenza vaccine manufacturer Crucell is aware of the current situation in Mexico and other affected countries. Crucell is in active dialogue with the relevant governmental authorities and non governmental organizations (NGOs), while suitable actions to the situation are being decided. As an active member of the International Vaccine Supply Task Force and the International Federation of Pharmaceutical Manufacturers and Associations, Crucell will work with other industry members, health authorities and NGOs to respond as rapidly as possible and in accordance with key recommendations made by the World Health Organization (WHO). In response to a request from the Pan American Health Organization, Crucell is looking to mobilize remaining (limited) stocks of its 2008/2009 seasonal vaccine Inflexal® V for supply to Mexico. Although at this stage it is not clear if existing seasonal flu vaccines induce protective immunity to the currently circulating H1N1 swine flu virus strain. The situation appears to be evolving rapidly, therefore Crucell's response will be tailored to support the public health needs, once more information becomes available, and as directed by organizations such as the WHO.

Crucell has an active influenza R&D program to improve the prevention and treatment of seasonal and pandemic influenza:

Crucell is testing new adjuvants and new routes of administration in humans for virosome-based pandemic influenza vaccines in the EU (Panfluvac program).
Sanofi Pasteur is using Crucell's PER.C6® technology to produce the next generation influenza vaccines.
Crucell has discovered human monoclonal antibodies broadly protecting against H1 strains to which family the current swine flu virus belongs. The most potent and broadly reactive of these antibodies is currently being prepared for clinical testing.
www.crucell.com/feature_Swineflu_stat...

Dat bedoel ik, kusje erbij!
*****************************
Baxter & Gilead Make Money From Swine Flu
Lee Brodie
CNBC
Tuesday, April 28, 2009
Stocks traded modestly lower by mid-day Monday. New details about the swine flu gave health care and biotech names a boost but dragged down the airlines, hotels and other travel & leisure names.
Shares of Baxter, GlaxoSmithKline, Crucell and Gilead all made gains on the potential that they could benefit from vaccines and treatments.
Both Crucell and Gilead are names that I’m watching explains Jon Najarian, because they both have a great deal of vaccine exposure. But they’re also trading down to their session lows, which suggests the panic may be abating.
Of course, there will be companies that make money from swine flu — it seems to me GlaxoSmithKline and Baxter are probably good plays on that, Najarian adds.
www.cnbc.com/id/30417735

[verwijderd] 28 april 2009 14:12

0

Site Crucell d.d. 28 april 2009

As an influenza vaccine manufacturer Crucell is aware of the current situation in Mexico and other affected countries. Crucell is in active dialogue with the relevant governmental authorities and non governmental organizations (NGOs), while suitable actions to the situation are being decided. As an active member of the International Vaccine Supply Task Force and the International Federation of Pharmaceutical Manufacturers and Associations, Crucell will work with other industry members, health authorities and NGOs to respond as rapidly as possible and in accordance with key recommendations made by the World Health Organization (WHO). In response to a request from the Pan American Health Organization, Crucell is looking to mobilize remaining (limited) stocks of its 2008/2009 seasonal vaccine Inflexal® V for supply to Mexico. Although at this stage it is not clear if existing seasonal flu vaccines induce protective immunity to the currently circulating H1N1 swine flu virus strain. The situation appears to be evolving rapidly, therefore Crucell's response will be tailored to support the public health needs, once more information becomes available, and as directed by organizations such as the WHO.

Crucell has an active influenza R&D program to improve the prevention and treatment of seasonal and pandemic influenza:

Crucell is testing new adjuvants and new routes of administration in humans for virosome-based pandemic influenza vaccines in the EU (Panfluvac program).
Sanofi Pasteur is using Crucell's PER.C6® technology to produce the next generation influenza vaccines.
Crucell has discovered human monoclonal antibodies broadly protecting against H1 strains to which family the current swine flu virus belongs. The most potent and broadly reactive of these antibodies is currently being prepared for clinical testing.

wilb52 28 april 2009 14:17

0

De radio was kapot in Leiden .
Is inmiddels gerepareerd, blijkbaar.

flosz 28 april 2009 14:25

0

quote:
wilb52 schreef:
De radio was kapot in Leiden .
Is inmiddels gerepareerd, blijkbaar.

Maar de mail en phone niet......

privee 28 april 2009 15:17

0

quote:
B_B schreef:
Yet there's possibly a way around this problem. Over the past few years, several companies have sprung up to develop methods for making vaccines more quickly, such as growing viruses in cells rather than eggs. These processes hold considerable promise, but none has been licensed yet by the Food & Drug Administration. One of the difficult decisions the Obama Administration will face if the epidemic threatens to spin out of control is whether to fast-track approval of one of these next-generation vaccines in order to make it available more quickly. "If this turns out to be a crisis, the government might go to one of the newer technologies that has quicker production," explains John Clerici, chair of the life sciences and public health practice at law firm McKenna Long & Aldridge. The bigger the crisis, the greater the tolerance for regulatory risks.

www.businessweek.com/technology/conte...

Zie hier enkele versoepelingen.

WASHINGTON (AP) -- The Food and Drug Administration has issued emergency guidance that allows certain antiviral drugs to be used in a broader range of the population in case mass dosing is needed to deal with a widespread swine flu outbreak.

The agency originally approved the use of the antiviral drug Tamiflu for the prevention and treatment of influenza in adults and children age 1 and older. Another antiviral drug, Relenza, was originally approved to treat people 7 and older and to help prevent flu in those 5 and older.

Late Monday, the FDA said it issued emergency guidance to allow Tamiflu to treat and prevent flu in children under 1 and to provide doses other than originally approved in children over 1. The drugs may be distributed to larger segments of the population without complying with the approved label requirements, the FDA said.

The agency also authorized a swine flu diagnostic test for testing samples from people with certain flu infections -- those whose virus subtypes cannot be identified by currently available tests.

finance.yahoo.com/news/FDA-approves-e...

flosz 28 april 2009 15:39

0

Farmaceuten aan de slag met varkensgriepvaccin
Uitgegeven: 28 april 2009 14:58
Laatst gewijzigd: 28 april 2009 14:58
AMSTERDAM - Farmaceuten hebben de eerste stappen genomen in de ontwikkeling van een vaccin tegen varkensgriep. Het Zwitserse Novartis heeft inmiddels de genetische code van de nieuwe virusvariant H1N1 ontvangen.
Er zijn wereldwijd minstens 20 bedrijven die griepvaccins maken. Volgens persbureau AP houden naast Novartis onder meer Sanofi-Aventis, GlaxoSmithKline en Baxter International zich hiermee bezig.
In Nederland ontwikkelt het biotechnologiebedrijf Crucell antilichamen tegen verschillende vormen van griep. Het Leidse concern boekte maandag een koersstijging van 8 procent op speculaties dat het een oplossing voor de varkensgriep kan bieden met zijn zogenoemde CR6261-antilichaam. Volgens een analist van RBS is die reactie echter ‘voorbarig’.
Maanden
Volgens de Wereldgezondheidsorganisatie WHO zal het echter nog vijf tot zes maanden in beslag nemen tot een eventueel vaccin tegen de varkensgriep commercieel beschikbaar is.
De farmaciesector is momenteel slechts toegerust voor de productie van de conventionele griepprik. Volgens specialisten zal dit niet afdoende zijn om de nieuwe variant een halt toe te roepen. Gevaccineerde mensen zullen waarschijnlijk hooguit mildere symtomen van de varkensgriep te verduren krijgen.
www.nuzakelijk.nl/20090428/algemeen/f...

Pakket met kweekjes varkensgriepvirus ontploft
In een Zwitserse trein is maandagavond een pakket met kweekjes van het varkensgriepvirus H1N1 ontploft. Het ging niet om de mutatie die in Mexico mogelijk 150 levens heeft geëist. Volgens de autoriteiten is er geen besmettingsgevaar door de explosie.
Het materiaal was bestemd voor een onderzoekscentrum voor griep in Genève. Door de explosie raakten twee mensen lichtgewond, aldus de Zwitserse politie.
Een medewerker van het instituut in Genève had in Zürich acht flessen met het virus opgehaald. Het materiaal werd in ijs met kooldioxide koel gehouden. Vermoedelijk was de explosie het gevolg van overdruk in het pakket.
www.depers.nl/buitenland/303395/Pakke...

[verwijderd] 28 april 2009 15:57

0

28 april 2009novum

Negatief reisadvies voor Mexico
(Novum) - Het ministerie van Buitenlandse Zaken raadt af om naar Mexico te reizen als dat niet noodzakelijk is. Reden is de uitbraak van varkensgriep, laat het departement dinsdag weten.

Alle zogeheten 'niet-essentiële' reizen worden ontraden. Wanneer het ministerie een dergelijk advies uitgeeft, is sprake van een 'verhoogd veiligheidsrisico' in het hele land.

De Wereldgezondheidsorganisatie WHO verhoogde maandag het alarmniveau als gevolg van de uitbraak. Er is sprake van een verhoogde kans op een wereldepidemie, nu er mens-op-mensbesmetting is geconstateerd.

"Ik raad iedereen aan om onze reisadviezen goed in de gaten te houden en de informatie op de site van het Rijksinstituut voor Volksgezondheid en Milieu en de WHO te volgen", aldus minister van Buitenlandse Zaken Maxime Verhagen (CDA) in een toelichting.

Het blijft echter de verantwoordelijkheid van de reiziger zelf en de touroperator om een reis naar Mexico al dan niet te laten doorgaan.

Dirk

www.trouw.nl/nieuws/nederland/article...

flosz 28 april 2009 15:58

0

Europe braced for spread of flu
More cases of swine flu in humans are likely to emerge across Europe in the coming days, EU Health Commissioner Androulla Vassiliou has warned.

In addition to Spain and the UK, Ms Vassiliou said suspected cases were also being investigated in the Republic of Ireland, Denmark, Germany, Italy, Sweden, Greece and the Czech Republic.
news.bbc.co.uk/1/hi/world/americas/80...
*******************
US Swine Flu Cases Rise To 45
In his first public remarks on the situation, President Obama urged Americans on Monday to remain calm as the number of US cases of swine flu more than doubled and the World Health Organization raised its pandemic threat level. As the confirmed number of US cases reached 45 yesterday, ABC World News reported that the President "urged calm." The President was shown saying: "This is obviously a cause for concern and requires a heightened state of alert. But it's not a cause for alarm." Obama, McClatchy reports, "worked...to assure the nation, and perhaps the world, that an outbreak of swine flu is a cause for concern but not alarm." And as "fears of a growing deadly global swine flu epidemic appear to be growing by the hour," CNN's The Situation Room noted that "from the President on down, the Obama Administration is moving quickly to calm Americans about a possible pandemic."
www.usnews.com/usnews/politics/bullet...
***************
CDC-teller staat nog op 40.
www.cdc.gov/swineflu/

flosz 28 april 2009 16:09

0

quote:
Dirk R. Wijnen schreef:
28 april 2009novum

Negatief reisadvies voor Mexico
(Novum) - Het ministerie van Buitenlandse Zaken raadt af om naar Mexico te reizen als dat niet noodzakelijk is. Reden is de uitbraak van varkensgriep, laat het departement dinsdag weten.
Alle zogeheten 'niet-essentiële' reizen worden ontraden. Wanneer het ministerie een dergelijk advies uitgeeft, is sprake van een 'verhoogd veiligheidsrisico' in het hele land.
De Wereldgezondheidsorganisatie WHO verhoogde maandag het alarmniveau als gevolg van de uitbraak. Er is sprake van een verhoogde kans op een wereldepidemie, nu er mens-op-mensbesmetting is geconstateerd.
"Ik raad iedereen aan om onze reisadviezen goed in de gaten te houden en de informatie op de site van het Rijksinstituut voor Volksgezondheid en Milieu en de WHO te volgen", aldus minister van Buitenlandse Zaken Maxime Verhagen (CDA) in een toelichting.
Het blijft echter de verantwoordelijkheid van de reiziger zelf en de touroperator om een reis naar Mexico al dan niet te laten doorgaan.

Ik hoop niet dat onderstaande een reden is alsnog te gaan.....

ROTTERDAM - Reizigers krijgen hun geld niet terug, als ze om de Mexicaanse griep hun reis naar een gebied waar de ziekte heerst, annuleren. Het Calamiteitenfonds keert alleen uit als mensen hun vakantie afzeggen bij natuurrampen en molest.
www.telegraaf.nl/reiskrant/3801827/
__Geen_geld_terug_bij_annulering_reis_om_Mexicaanse_griep__.html?p=20,1

wilb52 28 april 2009 16:21

0

Is er al een Swineflu gekonstateerd in het Rhein Gebiet, wo der Wein gemacht wird===
Nein=
Gut
Geh ich hin.

AEX 884,51 +5,80 +0,66% 13:31


Germany40^	17.961,70	+0,36%
BEL 20	3.921,95	+0,74%
Europe50^	4.915,16	+0,50%
US30^	38.480,03	+0,89%
Nasd100^	17.655,98	+0,82%
US500^	5.083,06	+0,38%
Japan225^	37.911,06	+0,26%
Gold spot	2.298,48	-0,23%
EUR/USD	1,0749	+0,22%
WTI	79,19	+0,30%

VIVORYON THER...	+9,15%
Flow Traders	+6,72%
Brunel	+5,08%
UMG	+2,65%
Alfen N.V.	+2,62%

HEIJMANS KON	-6,54%
Aperam	-3,75%
AMG Critical ...	-2,99%
OCI	-2,52%
BAM	-2,46%

Crucell « Terug naar discussie overzicht

Draadje varkensgriep

Meedoen aan de discussie?

Direct naar Forum

Markt vandaag

Aandelenadviezen van IEX.nl

Stijgers

Dalers